SIE, SIES, GITMO Evidence-Based Guidelines on Novel Agents (Thalidomide, Bortezomib, and Lenalidomide) in the Treatment of Multiple Myeloma.

A clinical practice guideline for patients with multiple myeloma. The guideline examines the use of thalidomide, bortezomib, and lenalidomide regimens with relation to autologous stem cell transplantation, and includes maintenance therapy recommendations. Risk factors such as age are also considered.